Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.87
+4.302.09%
Post-market: 210.740.8656+0.41%19:58 EDT
Volume:1.83M
Turnover:382.11M
Market Cap:44.98B
PE:-23.52
High:210.26
Open:204.64
Low:202.54
Close:205.57
52wk High:224.31
52wk Low:37.88
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.73
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.26
PE(LYR):-35.27

Loading ...

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

TIPRANKS
·
Aug 27

RBC Removes Speculative Risk From Revolution Medicines, Raises Price Target to $251 From $203, Keeps Outperform Rating

MT Newswires Live
·
Aug 27

Revolution Medicines price target raised to $280 from $195 at H.C. Wainwright

TIPRANKS
·
Aug 27

Revolution Medicines: Buy Rating Reiterated as FDA Approval and Strong Prelaunch Demand Support Unchanged $225 Price Target

TIPRANKS
·
Aug 27

U.S. Research Roundup-CrowdStrike, Nvidia, Macerich

Reuters
·
Aug 27

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS
·
Aug 27

Pancreatic Cancer Milestone: FDA Approves RevMed's Targeted Drug; 2032 Sales Seen Above $9B

Options & Short Sell
·
Aug 27

Revolution Medicines Earns Buy as RASONQUE FDA Approval and Strong Pricing Outlook Drive Price Target Increase to $315

TIPRANKS
·
Aug 27

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live
·
Aug 27

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
Aug 27

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
Aug 27

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Aug 26

Movement Alert|Revolution Medicines, Inc. Falls 5.34% in Regular Trading, Trading at $200.13

Market Focus
·
Aug 26

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26